L
9.04
-0.97 (-9.69%)
市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (US) | 混合的 | 混合的 |
| Biotechnology (全球的) | 混合的 | 混合的 | |
| 股票 | Lexeo Therapeutics, Inc. | 看涨 | 看跌 |
AIStockmoo 评分
1.6
| 分析师共识 | 4.0 |
| 内部交易活动 | NA |
| 价格波动 | -5.0 |
| 技术平均移动指标 | 3.5 |
| 技术振荡指标 | 4.0 |
| 平均 | 1.63 |
|
Lexeo Therapeutics Inc is a clinical-stage genetic medicines company committed to transforming healthcare by applying pioneering science to fundamentally alter how diseases are treated. The company focuses on preclinical and clinical stage gene therapies, specifically hereditary and acquired diseases with high unmet needs, which represent its sole business segment. |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
| 内部持股比例 | 0.75% |
| 机构持股比例 | 121.45% |
所有权
| 姓名 | 日期 | 持有股份 |
|---|---|---|
| Frazier Life Sciences Management, L.P. | 30 Jun 2025 | 4,424,725 |
| Affinity Asset Advisors, Llc | 30 Jun 2025 | 3,589,355 |
| Vestal Point Capital, Lp | 30 Jun 2025 | 3,228,161 |
| Woodline Partners Lp | 30 Jun 2025 | 2,572,162 |
| D1 Capital Partners L.P. | 30 Jun 2025 | 978,652 |
| Ally Bridge Group (Ny) Llc | 30 Jun 2025 | 867,302 |
| Point72 Asset Management, L.P. | 30 Jun 2025 | 647,880 |
| 52周波幅 | ||
| 目标价格波幅 | ||
| 高 | 30.00 (Guggenheim, 231.86%) | 购买 |
| 中 | 18.50 (104.65%) | |
| 低 | 13.00 (HC Wainwright & Co., 43.81%) | 购买 |
| 平均值 | 20.00 (121.24%) | |
| 总计 | 4 购买 | |
| 平均价格@调整类型 | 8.78 | |
| 公司 | 日期 | 目标价格 | 调整类型 | 价格@调整类型 |
|---|---|---|---|---|
| HC Wainwright & Co. | 21 Oct 2025 | 13.00 (43.81%) | 购买 | 9.60 |
| 07 Oct 2025 | 15.00 (65.93%) | 购买 | 8.34 | |
| Guggenheim | 15 Oct 2025 | 30.00 (231.86%) | 购买 | 8.83 |
| Chardan Capital | 07 Oct 2025 | 17.00 (88.05%) | 购买 | 8.34 |
| 15 Aug 2025 | 15.00 (65.93%) | 购买 | 4.72 | |
| Leerink Partners | 07 Oct 2025 | 20.00 (121.24%) | 购买 | 8.34 |
该时间范围内无数据。
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合